1至8批国家集采药品接续采购开标 千余家企业拟中选

Core Insights - The new round of national centralized procurement for medicines has resulted in 4,163 products from 1,020 companies being shortlisted, covering 316 commonly used drugs across 26 therapeutic areas [1][2] - The procurement results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028 [1] - The procurement process has seen a high participation rate from qualified companies, with an overall selection rate of 93%, indicating a diverse market supply and rich clinical choices [1] Group 1 - The centralized procurement is the first nationwide continuation of chemical drug procurement organized by the state, led by the medical insurance bureaus of Jiangsu, Henan, and Guangdong provinces [1] - The procurement rules have been standardized and unified across provinces, significantly reducing bidding costs for companies [1] - The clinical demand matching rate for the reported brand names reached 88%, with a high retention rate of previously selected products at 98%, which helps avoid medication replacement [1] Group 2 - The qualification threshold for bidding has been raised, with stricter quality requirements, including the need for companies to have experience in producing similar types of drugs and no violations of production quality management standards in the past two years [2] - The procurement adopted a pricing inquiry method based on previous winning prices, allowing companies to accurately calculate cost-benefit ratios and rationally quote prices, leading to stable selection prices and industry expectations [2]